Rituximab-pvvr is named as an intervention in 3 current clinical trials in our Israel, Canada, Mexico and Australia registers. None are recruiting at the moment. The most common phase is Phase 3. The sponsor with the most trials is National Cancer Institute (NCI) (2). The most-studied condition is Acute Lymphoblastic Leukemia.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
NCT02003222 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
|
Phase 3 | Active, closed | National Cancer Institute (NCI) | Canada, Israel |
|
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
NCT03984448 · Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma
|
Phase 2/3 | Active, closed | National Cancer Institute (NCI) | Mexico, Israel |
|
Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes
NCT03929601 · ClinicalTrials.gov ↗ · Type 1 Diabetes Mellitus
|
Phase 2 | Active, closed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 2 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Israel | 2 | 0 |
| Clinical trials in Canada | 1 | 0 |
| Clinical trials in Mexico | 1 | 0 |
| Clinical trials in Australia | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our Israel, Canada, Mexico and Australia registers name Rituximab-pvvr as a drug or biological intervention, as of the registry sync on 28 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 3 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
National Cancer Institute (NCI) (2) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Rituximab-pvvr works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Rituximab-pvvr works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Rituximab-pvvr (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Sep 2026.